The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Exciting developments in the myeloma space: CAR T-cells and bispecific antibodies
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares exciting developments in the treatment of multiple myeloma. Dr Lin highlights positive trial findings on CAR T-cells, as well as the potential of bispecific antibodies. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, we saw a lot of follow-ups, new data being presented from clinical trials. I would say one of the things that’s really most exciting to hear that I am sharing with all the patients I’m seeing in the clinic is the more than five-year follow-up we have now from the CARTITUDE-1 clinical trial. So I can tell these patients who are getting FDA-approved CAR-T that what we have seen from that first registration trial is close to one-third of these patients remaining in remission more than five years out post infusion and that in essence is a functional cure for them, right, not how we define curing in academics necessarily or statistically, but the fact that if they do respond to CAR-T, which the likelihood is extremely high, that they could stop taking maintenance medications and enjoy potentially good odds of staying in remission for a very long time...
Yeah, we saw a lot of follow-ups, new data being presented from clinical trials. I would say one of the things that’s really most exciting to hear that I am sharing with all the patients I’m seeing in the clinic is the more than five-year follow-up we have now from the CARTITUDE-1 clinical trial. So I can tell these patients who are getting FDA-approved CAR-T that what we have seen from that first registration trial is close to one-third of these patients remaining in remission more than five years out post infusion and that in essence is a functional cure for them, right, not how we define curing in academics necessarily or statistically, but the fact that if they do respond to CAR-T, which the likelihood is extremely high, that they could stop taking maintenance medications and enjoy potentially good odds of staying in remission for a very long time. So I’m very excited about that. Of course, we are seeing additional data coming out too from other CAR-T strategies, fast CAR-T, so a CAR-T that’s manufactured in under two days targeting CD19 and BCMA, the clinical trial has come out of China and now opened in the US, seeing some of the earlier line setting clinical trial results is very exciting, seeing some additional results coming out of anito-cel, as well, a different engineered CAR-T approach, also seeing very high response rates. So, you know, a lot of very exciting things coming. And then finally, bispecifics, I think, is something that could be even more broadly accessible for our patients across a variety of practices, and seeing some data coming out with trispecific, so not just targeting two, but three markers, two myeloma targets and engaging T-cells, some very promising response rates. And it’s a drug that is dosed really once a month, which could be, from a treatment burden standpoint, a big differentiator for our patients. So very excited to see all these results come out from these trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
